D
Delenex Therapeutics
Development of locally and systemically applied antibody therapeutic
About Delenex Therapeutics
Delenex Therapeutics AG was a clinical-stage biopharmaceutical company that operated out of Schlieren, Switzerland. The company was established in September 2009 as a spin-off from ESBATech AG, which was acquired by Alcon (a Novartis company). This strategic spin-off allowed Delenex to retain the rights to ESBATech's clinically validated antibody technology for all applications outside of ophthalmology.
The company focused on developing antibody therapeutics for diseases with high unmet medical needs, particularly in dermatology and other inflammatory conditions. Delenex's business model revolved around leveraging its proprietary PENTRA®Body platform to create treatments that were more accessible than traditional antibody therapies. These therapies were often injectable, expensive, and carried a risk of side effects, limiting their use to patients with severe conditions. Delenex aimed to provide therapies for mild-to-moderate patient populations at a lower cost.
The core of Delenex's offering was its PENTRA®Body technology. This platform produced small, highly potent, and stable human antibody fragments (scFv). A key feature of these antibody fragments was their superior ability to penetrate tissues, which made them suitable for topical or local administration. This approach offered several benefits: it required less drug for the same therapeutic effect, lowered production costs, minimized systemic side effects, and allowed for patient self-administration, reducing overall healthcare costs. The company's pipeline included candidates targeting conditions like psoriasis, acne, and Crohn's disease. For example, their lead compound, DLX105, an anti-TNFα PENTRA®Body, showed it could suppress inflammatory cytokines in the skin of psoriasis patients when applied topically.
In November 2010, Delenex secured CHF 13.5 million in a Series A financing round from a syndicate of venture capital firms, including SV Life Sciences and HBM Partners, who were previous investors in ESBATech. This funding was critical for advancing its pipeline. The management team included experienced individuals such as Thomas Hecht (Executive Chairman), Titus Kretzschmar (Chief Scientific Officer), and Hamish Cameron (Business Development). A significant milestone occurred in July 2016 when Cell Medica, a London-based cellular immunotherapy company, acquired Delenex for an undisclosed amount. The acquisition was driven by Cell Medica's goal to integrate Delenex's PENTRA® platform to accelerate the development of next-generation Chimeric Antigen Receptor (CAR)-modified cellular immunotherapies for cancer. Following the acquisition, the Delenex scientific team and its laboratory facilities were integrated into Cell Medica's R&D operations and renamed Cell Medica Switzerland AG.
Source: Dealroom company dataNews
Open roles
Delenex Therapeutics in the Schlieren ecosystem
The Delenex Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
VI Partners
BioMedVC
SV Health Investors
HBM Healthcare Investments
Novo Ventures
Series B and later1 investor entered at this stage
ESBATech
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Delenex Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Delenex Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

